Dr. Jean-Paul Bahary, MD

Claim this profile

CHUM - Hopital Notre-Dame

Studies Glioblastoma
Studies Gliosarcoma
3 reported clinical trials
8 drugs studied

Affiliated Hospitals

Image of trial facility.
CHUM - Hopital Notre-Dame
Image of trial facility.
CHUM-Centre Hospitalier De L'Universite De Montreal

Clinical Trials Jean-Paul Bahary, MD is currently running

Image of trial facility.

Radiation Therapy vs Observation

for Meningioma

This trial studies if radiation therapy helps prevent the return of grade II meningioma after surgery. Radiation therapy uses powerful x-rays to destroy any leftover cancer cells. The goal is to see if this improves patient outcomes compared to just monitoring them. Radiation therapy has shown success in stabilizing tumor growth and reducing recurrence risk.
Recruiting2 awards Phase 312 criteria
Image of trial facility.

Multimodal Therapy

for Brain AVM

The objectives of this study and registry are to offer the best management possible for patients with brain arteriovenous malformations (AVMs) (ruptured or unruptured) in terms of long-term outcomes, despite the presence of uncertainty. Management may include interventional therapy (with endovascular procedures, neurosurgery, or radiotherapy, alone or in combination) or conservative management. The trial has been designed to test a) whether medical management or interventional therapy will reduce the risk of death or debilitating stroke (due to hemorrhage or infarction) by an absolute magnitude of about 15% (over 10 years) for unruptured AVMs (from 30% to 15%); and, b) to test if endovascular treatment can improve the safety and efficacy of surgery or radiation therapy by at least 10% (80% to 90%). As for the nested trial on the role of embolization in the treatment of Brain AVMs by other means: the pre-surgical or pre-radiosurgery embolization of cerebral AVMs can decrease the number of treatment failures from 20% to 10%. In addition,embolization of cerebral AVMs can be accomplished with an acceptable risk, defined as permanent disabling neurological complications of 8%.
Recruiting1 award N/A1 criteria

More about Jean-Paul Bahary, MD

Clinical Trial Related9 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Jean-Paul Bahary, MD has experience with
  • Temozolomide
  • Photon Beam Radiation Therapy
  • Proton Beam Radiation Therapy
  • Clinical Observation
  • Radiation Therapy
  • Neurosurgery

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jean-Paul Bahary, MD specialize in?
Jean-Paul Bahary, MD focuses on Glioblastoma and Gliosarcoma. In particular, much of their work with Glioblastoma has involved treating patients, or patients who are undergoing treatment.
Is Jean-Paul Bahary, MD currently recruiting for clinical trials?
Yes, Jean-Paul Bahary, MD is currently recruiting for 2 clinical trials in Montreal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Jean-Paul Bahary, MD has studied deeply?
Yes, Jean-Paul Bahary, MD has studied treatments such as Temozolomide, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy.
What is the best way to schedule an appointment with Jean-Paul Bahary, MD?
Apply for one of the trials that Jean-Paul Bahary, MD is conducting.
What is the office address of Jean-Paul Bahary, MD?
The office of Jean-Paul Bahary, MD is located at: CHUM - Hopital Notre-Dame, Montreal, Quebec H2L 4M1 Canada. This is the address for their practice at the CHUM - Hopital Notre-Dame.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.